CA
CRL icon

CGN Advisors’s Charles River Laboratories CRL Stock Holding History

CGN Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-7,476
Closed -$1.13M – 300
2025
Q1 		$1.13M Sell
7,476
-1,185
-14% -$199K 0.11% 163
2024
Q4 		$1.6M Sell
8,661
-1,119
-11% -$216K 0.16% 129
2024
Q3 		$1.93M Buy
9,780
+490
+5% +$102K 0.19% 118
2024
Q2 		$1.92M Buy
9,290
+1,370
+17% +$310K 0.22% 111
2024
Q1 		$2.15M Buy
7,920
+887
+13% +$212K 0.27% 98
2023
Q4 		$1.66M Buy
+7,033
New +$1.38M 0.23% 117

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

CGN Advisors's CRL Position: Q2 2025 in Review

CGN Advisors sold out of Charles River Laboratories (CRL) in Q2 2025, closing a stake of 7,476 shares — an estimated $1.13M sold.

CGN Advisors first reported a position in CRL in Q4 2023 and held it in 6 quarters. The position peaked at $2.15M in Q1 2024. 519 funds tracked by Wall St. Rank hold CRL as of Q2 2025.

  • CGN Advisors reported no remaining Charles River Laboratories position as of Q2 2025 after selling out during the quarter.
  • CGN Advisors sold 7,476 Charles River Laboratories shares in Q2 2025, an estimated $1.13M.
  • CGN Advisors first reported a position in Charles River Laboratories in Q4 2023 and held it in 6 quarters.
  • CGN Advisors's Charles River Laboratories position peaked at $2.15M in Q1 2024.
  • 519 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2025.

Based on CGN Advisors's 13F filing for Q2 2025, filed 15 Jul 2025.